MARKET

PYPD

PYPD

PolyPid Ltd.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

7.78
+0.17
+2.23%
Closed 16:00 09/17 EDT
OPEN
7.68
PREV CLOSE
7.61
HIGH
7.80
LOW
7.56
VOLUME
10.90K
TURNOVER
--
52 WEEK HIGH
16.50
52 WEEK LOW
6.95
MARKET CAP
127.76M
P/E (TTM)
-4.3607
1D
5D
1M
3M
1Y
5Y
JMP Securities Initiates Coverage On PolyPid with Market Outperform Rating, Announces Price Target of $14
JMP Securities initiates coverage on PolyPid (NASDAQ:PYPD) with a Market Outperform rating and announces Price Target of $14.
Benzinga · 4d ago
PolyPid Says Pre-Clinical OncoPLEX Data Shows Tumor Growth Inhibition
MT Newswires · 5d ago
PolyPid Shares Preclinical Data Of OncoPLEX Program For Brain Tumor
Benzinga · 5d ago
A Look Into Healthcare Sector Value Stocks
What Defines a Value Stock? A value stock is traditionally defined in terms of how investors in the marketplace are valuing that company's future growth prospects. Low P/E multiples are good base indicators that the company is undervalued and can most lik...
Benzinga · 5d ago
PolyPid Announces Preclinical Data In Glioblastoma Multiform Animal Models Of OncoPLEX Program; Says Results Demonstrated 'Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival'
Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged Survival   Company Expects a
Benzinga · 5d ago
PolyPid Announces Positive Preclinical Data of its Intra-tumoral OncoPLEX in Brain Cancer
Positive Results in Two Animal Models of Glioblastoma Multiform (GBM) demonstrated that Single Local Treatment of OncoPLEX Significantly Inhibited Tumor Growth and Prolonged SurvivalCompany Expects a Pre-IND Meeting with the U.S. FDA by Year End and Potent...
GlobeNewswire · 5d ago
PolyPid to Present at First World Association Against Infection in Orthopaedics and Trauma Congress
PolyPid Ltd. (Nasdaq: PYPD), a late-stage biopharma focusing on developing targeted, locally administered and prolonged-release therapeutics to improve surgical outcomes, announced today that its Co-Founder and Chief Scientific Officer Dr. Noam Emanuel, wi...
GlobeNewswire · 08/17 12:00
PolyPid Q2 EPS $(0.56) Misses $(0.52) Estimate
PolyPid (NASDAQ:PYPD) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate of $(0.52) by 7.69 percent. This is a 91.21 percent increase over losses of $(6.37) per share from the same
Benzinga · 08/11 11:29
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of PYPD. Analyze the recent business situations of PolyPid Ltd. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average PYPD stock price target is 23.86 with a high estimate of 30.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 28
Institutional Holdings: 1.64M
% Owned: 10.00%
Shares Outstanding: 16.42M
TypeInstitutionsShares
Increased
8
78.57K
New
5
60.08K
Decreased
6
82.44K
Sold Out
3
16.79K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-0.40%
Pharmaceuticals & Medical Research
-0.10%
Key Executives
Chairman/Director
Anat Segal
Chief Executive Officer/Director
Amir Weisberg
Chief Financial Officer/Primary Contact
Shaun Marcus
Chief Operating Officer/Director
Jack Kyiet
Chief Technology Officer/Director
Noam Emanuel
No Data
About PYPD
Polypid Ltd is a biopharmaceutical company at the clinical stage, based in Israel . The company focuses on the development, production and commercialization of new, locally administered therapies to improve surgical results. The main product is PLEX technology, which is located in the place of surgery and ensures controlled and continuous delivery of medicines.

Webull offers kinds of Polypid Ltd stock information, including NASDAQ:PYPD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PYPD stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading PYPD stock methods without spending real money on the virtual paper trading platform.